Table 7.

Incidences of adjudication-confirmed cases of pancreatitis and prespecified hypersensitivity adverse events in the APaT population; Treatment Period + all follow-up days

Patients, n (%)	Omarigliptin N = 2092	Placebo N = 2100
With pancreatitis
Acute	6 (0.3)	3 (0.1)
Chronic	0 (0.0)	1 (<0.1)
With hypersensitivity
Angioedema	4 (0.2)	1a (0.1)
Asthma–bronchospasm	2 (0.1)	2 (0.1)
Anaphylaxis	0 (0.0)	1 (<0.1)

^aOne patient in the placebo group was reported to have experienced two cases of angioedema